Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mucolytics: when dispensable, when necessary?

P Dorow1

  • 1Abteilung Pneumologie, Freien Universität Berlin, Federal Republic of Germany.

Lung
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diagnosis of acute pulmonary embolism. Recommendations of the German Society of Pneumology].

Pneumologie (Stuttgart, Germany)·2001
Same author

MRI and CT in the differential diagnosis of pleural disease.

Chest·2000
Same author

Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group.

Respiratory medicine·2000
Same author

Kinin generation in acute pneumonia and chronic bronchitis.

The European respiratory journal·1997
Same author

[Restless legs syndrome and periodic leg movements during sleep in patients with sleep apnea--a therapeutic problem?].

Pneumologie (Stuttgart, Germany)·1997
Same author

[Effect of long-term oxygen therapy on sleep architecture in patients with severe dilated cardiomyopathy and Cheyne-Stokes respiration].

Pneumologie (Stuttgart, Germany)·1997
Same journal

Circulating Adipokines as Diagnostic and Prognostic Markers in Idiopathic Pulmonary Fibrosis.

Lung·2026
Same journal

Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.

Lung·2026
Same journal

Social Vulnerability Index is Associated with Increased Risk of Malignancy in Screen-Detected High-Risk Pulmonary Nodules.

Lung·2026
Same journal

Validation Approaches for Cough Monitoring Tools: A Scoping Review.

Lung·2026
Same journal

Serological Profiling and Neuro-Immune Resilience: The Dissociation Between Anti-SARS-CoV-2 Antibodies and Post-Viral Airway Hyperresponsiveness in Pediatric Asthma.

Lung·2026
Same journal

Salvinorin A Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization and Macrophage-to-Myofibroblast Transition.

Lung·2026
See all related articles

Mucolytic drugs help patients with chest disease clear mucus by changing its properties. This review discusses the effectiveness of mucolytic therapy for improving chest conditions.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Patients with chest disease often struggle with sputum expectoration.
  • Various agents are employed to aid mucus clearance.
  • Mucolytic drugs offer a therapeutic approach to manage mucus viscosity.

Purpose of the Study:

  • To review the effectiveness of mucolytic therapy in patients with chest disease.
  • To discuss the mechanisms of action of mucolytic agents.

Main Methods:

  • This paper reviews existing literature on mucolytic therapy.
  • It examines the direct and indirect effects of mucolytics on mucus.

Main Results:

  • Mucolytic drugs modify mucus rheology by direct action or by influencing mucus-secreting cells.

Related Experiment Videos

  • These agents have the potential to benefit both physicians and patients.

    • Conclusions:

    • Mucolytic therapy is a valuable option for managing sputum retention in chest diseases.
    • Further understanding of mucolytic mechanisms can optimize patient outcomes.